FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/069,307	ATTY. DOCKET NO.: B1136.70000US03
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 9/26/2002	CONFIRMATION NO.: 1962
	APPLICANT: Edward Ingenito	
Sheet 1 of 1	GROUP ART UNIT: 3763	EXAMINER: C.S. Williams

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/QNV/		BERGERON, M. et al., "Pharmacodynamics of antibiotics in fibrin clots", Journal of Antimicrobial Chemotherapy (1993) 31, Suppl. D, 113-136	

EXAMINER: /Quynh-nhu Vu/	DATE CONSIDERED: 12/26/2007

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. nclude copy of this form with next communication to Applicant.

a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __ , filed __ , and relied upon for an earlier iling date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, re included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are rovided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is elied upon for an earlier filing date under 35 U.S.C. §120.]

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/069,307-Conf. #1962
Filing Date	September 26, 2002
First Named Inventor	Edward P. Ingenito
Art Unit	3763
Examiner Name	C. S. Williams
Attorney Docket Number	B1136.70000US03

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/QNV/	A1	US-20030099601-A1	05-29-2003	Gordon et al.	
	A2	US-20030114384-A1	06-19-2003	Podolsky	
	A3	US-20030134810-A1	07-17-2003	Springate et al.	
	A4	US-20030181356-A1	09-25-2003	Ingenito	
	A5	US-20040038868-A1	02-26-2004	Ingenito	
	A6	US-20040047855-A1	03-11-2004	Ingenito	
	A7	US-20050130176	06-16-2005	Vogelstein et al.	
	A8*	US-3,089,815	05-14-1963	Lieb et al.	
	A9	US-4,013,507	03-22-1977	Rembaum	
	A10	US-4,393,041	07-18-1983	Brown et al.	
	A11	US-4,442,655	04-17-1984	Stroetmann	
	A12	US-4,619,913	10-28-1986	Luck	
	A13	US-4,631,055	12-23-1986	Redl et al.	
	A14	US-4,719,282	01-12-1988	Nadolsky et al.	
	A15	US-4,973,582	11-27-1990	Yoshida et al.	
	A16	US-5,290,552	03-23-1992	Sierra et al.	
	A17	US-5,583,114	12-10-1996	Barrows et al.	
	A18	US-5,651,982	07-29-1997	Marx	
	A19	US-5,660,175	08-26-1997	Dayal	
	A20	US-5,690,675	11-25-1997	Sawyer et al.	
	A21	US-5,714,470	02-03-1998	Peet et al.	
	A22	US-5,780,440	07-14-1998	Lezdey et al.	
	A23	US-5,836,905	11-17-1998	Lemelson et al.	
	A24	US-5,883,084	03-16-1999	Peterson et al.	
	A25	US-5,980,866	11-09-1999	Uchida et al.	
	A26	US-6,001,814	12-14-1999	Gyorkos et al.	
	A27	US-6,117,425	09-12-2000	MacPhee et al.	
	A28	US-6,123,663	09-26-2000	Rebuffat et al.	
	A29	US-6,258,100	07-10-2001	Alferness et al.	
	A30	US-6,293,951	09-25-2001	Alferness et al.	
	A31	US-6,333,194	12-25-2001	Levy et al.	
	A32	US-6,592,594	07-15-2003	Rimbaugh et al.	
	A33	US-6,599,311	07-29-2003	Biggs et al.	
	A34	US-6,645,205	11-11-2003	Ginn	
	A35	US-6,837,906	01-04-2005	Ginn	
	A36	US-6,878,141	04-12-2005	Perkins et al.	
	A37	US-6,886,558	05-03-2005	Tanaka	
	A38	US-6,929,637	08-16-2005	Gonzalez et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
/QNV/	B1	EP-0627266	12-07-1994	Aid Medic Ltd		
	B2	EP-1206276	05-22-2002	Ingenito Edward P		
	B3	RU-2092108	10-10-1997	Vecherko Vladimir Nikolaevich et al.		√

Examiner Signature	/Quynh-nhu Vu/	Date Considered	12/26/2007

1236579

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 4

Complete If Known	
Application Number	10/069,307-Conf. #1962
Filing Date	September 26, 2002
First Named Inventor	Edward P. Ingenito
Art Unit	3763
Examiner Name	C. S. Williams
Attorney Docket Number	B1136.70000US03

/QNV/	B4	RU-2130946	05-27-1999	Ehmakjur Biotek Ink		√
	B5	WO-0113908	03-01-2001	Ingenito Edward P		
	B6	WO-0126721	04-19-2001	Univ Boston et al.		
	B7	WO-03105676	12-24-2003	Bistech Inc et al.		
	B8	WO-9209301	06-11-1992	American Nat Red Cross et al.		
	B9	WO-9213547	08-20-1992	Eaton et al.		
	B10	WO-9407607	04-14-1994	Boehringer Ingelheim Int et al.		
	B11	WO-9613292	05-09-1996	Aradigm Corp		
	B12	WO-9616983	06-06-1996	Jolla Cancer Res Found		
	B13	WO-9729851	08-21-1997	Technology Partnership et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
/QNV/	C1	[No Author Listed] Surfactant replacement therapy for respiratory distress syndrome. American Academy of Pediatrics. Committee on Fetus and Newborn. Pediatrics. 1999 Mar;103(3):684-5.	
	C2	[No Author Listed] Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980 Sep;93(3):391-8.	
	C3	BAUMANN et al., Closure of a bronchopleural fistula using decalcified human spongiosa and a fibrin sealant. Ann Thorac Surg. 1997 Jul;64(1):230-3.	
	C4	BERLIN et al., Are porphyrin mixtures favorable photodynamic anticancer drugs? A model study with combinatorial libraries of tetraphenylporphyrins. Comb Chem. 1998;61:107-8.	
	C5	CAMILLI et al., Longitudinal changes in forced expiratory volume in one second in adults. Effects of smoking and smoking cessation. Am Rev Respir Dis. 1987 Apr;135(4):794-9.	
	C6	CARR et al., Effect of homo poly(L-amino acids) on fibrin assembly: role of charge and molecular weight. Biochemistry, Vol. 28, No. 3 (1989) 1388-1395.	
	C7	CARR et al., Effect of glycosaminoglycans on Thrombin- and atroxin-induced fibrin assembly and structure. 62(4) 1057-1061 (1989).	
	C8	COYLE et al., Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. J Clin Invest. 1995 Apr;95(4):1735-40.	
	C9	DALLAS et al., Measuring interactions between ECM and TGFß-like proteins. Chapter 19: Methods in Molecular Biology. 2000;139:231-43.	
	C10	DANIEL et al., Lung volume reduction surgery. Case selection, operative technique, and clinical results. Ann Surg. 1996 May;223(5):526-31; discussion 532-3.	
	C11	DEYERLING et al., A suspension of fibrin glue and antibiotic for local treatment of mycotic aneurysms in endocarditis--an experimental study. Thorac Cardiovasc Surg. 1984 Dec;32(6):369-72.	
	C12	DRUMMOND et al., Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999 Dec;51(4):691-743.	
	C13	FESSLER et al., Lung volume reduction surgery and airflow limitation. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):715-22.	
	C14	FOK et al.; Randomised controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1999	

Examiner Signature	/Quynh-nhu Vu/	Date Considered	12/26/2007

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	10/069,307-Conf. #1962
Filing Date	September 26, 2002
First Named Inventor	Edward P. Ingenito
Art Unit	3763
Examiner Name	C. S. Williams
Attorney Docket Number	B1136.70000US03

		May;80(3):F203-8.	
/QNV/	C15	GELB et al., Lung function 5 yr after lung volume reduction surgery for emphysema. Am J Respir Crit Care Med. 2001 Jun;163(7):1562-6.	
	C16	GILMAN et al., The role of the carbohydrate moiety in the biologic properties of fibrinogen. J Biol Chem. 1984 Mar 10;259(5):3248-53.	
	C17	GOLAB et al., Potentiation of the anti-tumour effects of Photofrin-based photodynamic therapy by localized treatment with G-CSF. Br J Cancer. 2000 Apr;82(8):1485-91.	
	C18	GRISHAKOV et al., Temporary endobronchial occlusion in a complex treatment of purulent-destructive lesions of the lungs and pleura. Synopsis of the Candidate of Sciences degree thesis. 1988. Russian	√
	C19	GUSTAFSSON et al., The 21-residue surfactant peptide (LysLeu4)4Lys(KL4) is a transmembrane alpha-helix with a mixed nonpolar/polar surface. FEBS Lett. 1996 Apr 15;384(2):185-8.	
	C20	HANTOS et al., Mechanical impedances of lungs and chest wall in the cat. J Appl Physiol. 1992 Aug;73(2):427-33.	
	C21	HAUTAMAKI et al., Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997 Sep 26;277(5334):2002-4.	
	C22	HÜRTER et al., Endobronchial sonography: feasibility and preliminary results. Thorax. 1992 Jul;47(7):565-7.	
	C23	INGENITO et al., Biophysical characterization and modeling of lung surfactant components. J Appl Physiol. 1999 May;86(5):1702-14.	
	C24	INGENITO et al., Pivotal role of anionic phospholipids in determining dynamic behavior of lung surfactant. Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):831-8.	
	C25	INGENITO et al., Comparison of physiological and radiological screening for lung volume reduction surgery. Am J Respir Crit Care Med. 2001 Apr;163(5):1068-73.	
	C26	INGENITO et al., Interpreting improvement in expiratory flows after lung volume reduction surgery in terms of flow limitation theory. Am J Respir Crit Care Med. 2001 Apr;163(5):1074-80.	
	C27	INGENITO et al., Bronchoscopic volume reduction: a safe and effective alternative to surgical therapy for emphysema. Am J Respir Crit Care Med. 2001 Jul 15;164(2):295-301.	
	C28	INNIS et al., Evolutionary trace analysis of TGF-beta and related growth factors: implications for site-directed mutagenesis. Protein Eng. 2000 Dec;13(12):839-47.	
	C29	ITOH et al., [A fibrin clot containing of anticancer drug for intra-arterial chemo-embolization therapy. (1) Experimental study on basic characteristics in dogs] Gan To Kagaku Ryoho. 1985 Feb;12(2):250-7. Japanese.	
	C30	KÖNIG et al., Pdt of tumor-bearing mice using liposome delivered texaphyrins. International Conference, Milan, Italy. June 24-27, 1992.	
	C31	KONONOV et al., Roles of mechanical forces and collagen failure in the development of elastase-induced emphysema. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1920-6.	
	C32	KREIMER-BIRNBAUM et al., Modified porphyrins, chlorins, phthalocyanines, and purpurins: second-generation photosensitizers for photodynamic therapy. Semin Hematol. 1989 Apr;26(2):157-73.	
	C33	KUSANAGI et al., Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol Biol Cell. 2000 Feb;11(2):555-65.	
	C34	LALVANI et al., Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med. 2001 Mar;163(4):824-8.	
	C35	LEBOEUF, et al. Effects of hyaluronic acid and other glycosaminoglycans on fibrin polymer formation. Biochemistry 1987, 26 6052-6057.	
	C36	LIN et al., Induction of pulmonary fibrosis in organ-cultured rat lung by cadmium chloride and transforming growth factor-beta1. Toxicology. 1998 May 15;127(1-3):157-66.	

Examiner Signature	/Quynh-nhu Vu/	Date Considered	12/26/2007

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/069,307-Conf. #1962
Filing Date	September 26, 2002
First Named Inventor	Edward P. Ingenito
Art Unit	3763
Examiner Name	C. S. Williams
Attorney Docket Number	B1136.70000US03

/QNV/	C37	LIPP et al., Phase and morphology changes in lipid monolayers induced by SP-B protein and its amino-terminal peptide. Science. 1996 Aug 30;273(5279):1196-9.	
	C38	MCKENNA et al., Should lung volume reduction for emphysema be unilateral or bilateral? J Thorac Cardiovasc Surg. 1996 Nov;112(5):1331-8; discussion 1338-9.	
	C39	MCLEAN et al., An amphipathic alpha-helical decapeptide in phosphatidylcholine is an effective synthetic lung surfactant. Am Rev Respir Dis. 1993 Feb;147(2):462-5.	
	C40	NEY et al., Fibrin glue-antibiotic suspension in the prevention of prosthetic graft infection. J Trauma. 1990 Aug;30(8):1000-5; discussion 1005-6.	
	C41	NILSSON et al., Synthetic peptide-containing surfactants--evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution. Eur J Biochem. 1998 Jul 1;255(1):116-24.	
	C42	OTIS et al., Dynamic surface tension of surfactant TA: experiments and theory. J Appl Physiol. 1994 Dec;77(6):2681-8.	
	C43	PASS et al., Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst. 1993 Mar 17;85(6):443-56.	
	C44	RICHERT et al., A long-time-stable liposome formulation for porphyrinoid photosensitizers. J Photochem Photobiol B: Biol. 1993;19:67-73.	
	C45	SHAPIRO et al., The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 2):S29-32.	
	C46	SIME et al., Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997 Aug 15;100(4):768-76.	
	C47	SMITH et al., Activity of two polyene and two imidazole antimicrobics on Candida albicans in human fibrin clots. J Lab Clin Med. 1983 Jul;102(1):126-32.	
	C48	SUGITACHI et al., Japan J Cancer Chemother 16(8)2814-2817 August 1989. (Abstract)	
	C49	SUKI et al., On the progressive nature of emphysema: roles of proteases, inflammation and mechanical forces. Am. J. of Resp. and Critical Care Med. Vol. 168 516-521 (2003).	
	C50	VAROLI et al., Endoscopic treatment of bronchopleural fistulas. Ann Thorac Surg. 1998 Mar;65(3):807-9.	
	C51	WHITMAN et al., TGF-beta superfamily signaling and left-right asymmêtry. Sci STKE. 2001 Jan 9;2001(64):RE1.	
	C52	YANAGISAWA et al., [Endoscopic closure of the postoperative bronchopleural fistula] Kyobu Geka. 1992 Oct;45(11):975-8. Japanese.	
↓	C53	ZIESCHE et al., A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999 Oct 21;341(17):1264-9. Erratum in: N Engl J Med 2000 Feb 17;342(7):524.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. [1] Applicant's unique citation-designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Quynh-nhu Vu/	Date Considered	12/26/2007